NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-CA-21-117 from the NIH Guide for Grants and Contracts
Notice NOT-DA-21-081 from the NIH Guide for Grants and Contracts
Notice NOT-NS-22-026 from the NIH Guide for Grants and Contracts
Notice NOT-DA-21-074 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-RM-21-026 from the NIH Guide for Grants and Contracts. This FOA seeks to support state-of-the-art Tissue Mapping Centers (TMCs) that will serve as the core data generators for the HuBMAP Consortium by generating a high-resolution, multi-parameter, 3D atlas of a non-diseased human organ. Successful centers will build, benchmark, and standardize pipelines for generating, validating and analyzing data from multiplexed, high-throughput imaging and omics technologies. Centers will be expected to integrate and optimize all parts of the data generation pipeline, from tissue collection and preservation through to data integration, analysis and interpretation in order to build high-resolution maps. Centers will use these maps to provide new insights into intra-, inter- and extra- cellular organizational features that influence tissue function, vary across individuals or that change across the lifespan. By the end of four years of funding, a successful center will have created a significant number of high-resolution, multi-scale, multi-dimensional molecular, cellular and morphological maps from multiple donors that are integrated into a published reference atlas for that organ.
Global Brain and Nervous System Disorders Research Across the Lifespan (R21 Clinical Trial Optional)
Funding Opportunity PAR-21-319 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages exploratory/developmental research grant applications, proposing the development of innovative, collaborative research projects on brain and other nervous system function and disorders throughout life, relevant to low- and middle-income countries (LMICs). Research on neurological, mental, behavioral, alcohol and substance use disorders may span the full range of science from basic to implementation research. Scientists in the United States (U.S.) or upper-middle income countries (UMICs) are eligible to partner with scientists in LMIC institutions. Scientists in upper middle-income LMICs (UMICs) are also eligible to partner directly with scientists at other LMIC institutions with or without out a US partner. Income categories used are as defined by the World Bank at http://data.worldbank.org/about/country-classifications/country-and-lending-groups. These grants are expected to foster the development of more comprehensive research programs that contribute to the long-term goals of building sustainable research capacity in LMICs to address nervous system development, function and impairment throughout life and to lead to diagnostics, prevention, treatment and implementation strategies. The proposed work may also contribute to developing a base for research networking and evidence-based policy beyond the specific research project.
Funding Opportunity PAR-21-311 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages grant applications for the conduct of innovative, collaborative research projects between U.S. and low- and middle-income country (LMIC) scientists, on brain and other nervous system function and disorders throughout life, relevant to LMICs (including neurological, mental, behavioral, alcohol and substance use disorders and spanning the full range of science from basic to implementation research). Scientists in upper middle-income LMICs (UMICs) are also eligible to partner directly with scientists at other LMIC institutions with or without out a US partner. Income categories are defined by the World Bank at http://data.worldbank.org/about/country-classifications/country-and-lending-groups.
Notice NOT-OD-21-183 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-21-327 from the NIH Guide for Grants and Contracts. The objective of the NIH Career Transition Award (K22) is to provide support to outstanding basic or clinical investigators to develop their independent research skills through a two phase program: an initial period involving an intramural appointment at the NIH and a final period of support at an extramural institution. This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities.
Funding Opportunity PAR-21-328 from the NIH Guide for Grants and Contracts. The objective of the NIH Career Transition Award (K22) is to provide support to outstanding basic or clinical investigators to develop their independent research skills through a two phase program: an initial period involving an intramural appointment at the NIH and a final period of support at an extramural institution. This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities.
Funding Opportunity PAR-21-301 from the NIH Guide for Grants and Contracts. The purpose of the NCI Transition Career Development Award to Promote Diversity (K22) is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist
Funding Opportunity PAR-21-302 from the NIH Guide for Grants and Contracts. The purpose of the NCI Transition Career Development Award to Promote Diversity is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. To this end, the Diversity Training Branch (DTB), within the Center to Reduce Cancer Health Disparities (CRCHD) (http://crchd.cancer.gov/) invites applications from research scientists in postdoctoral positions or equivalent who are from backgrounds nationally underrepresented in biomedical, behavioral, clinical, and/or social sciences. This award will provide "protected time" through salary and research support for 3 years beginning at the time when the candidate starts a tenure-track faculty position.
Funding Opportunity PAS-21-270 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) seeks to facilitate the entry of both newly independent and early career investigators to the area of drug use and use disorder research and HIV/AIDS. This FOA, the AIDS-Science Track Award for Research Transition (A-START), encourages Small Research Grant (R03) applications to support research projects on drug use and/or use disorder and HIV/AIDS that can be carried out in a short period of time with limited resources. This FOA welcomes applications integrating substance use and/or substance use disorder (SUD) and HIV/AIDS across all areas of research supported by NIDA.
Notice NOT-AA-21-042 from the NIH Guide for Grants and Contracts
Notice NOT-OD-21-181 from the NIH Guide for Grants and Contracts
Notice NOT-NS-22-023 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-21-345 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) hereby notify Small Business Concerns (SBCs) holding Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants that funds are available for administrative supplements to improve the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from groups that have been shown to be nationally underrepresented in health-related research or in the SBIR and STTR programs. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project. Administrative supplements must support work within the scope of the original project. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.
Notice NOT-AG-21-061 from the NIH Guide for Grants and Contracts
The Human BioMolecular Atlas Program (HuBMAP) Demonstration Project (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-RM-21-027 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity announcement is to solicit applications that will creatively use datasets and resources from the Human BioMolecular Atlas Program (HuBMAP: https://commonfund.nih.gov/hubmap) to demonstrate their use to address significant biomedical and biological questions. Projects are expected to work closely with the other funded projects as part of the HuBMAP Consortium to provide specific and actionable feedback, validations, tools, software and other resources back to the consortium.
Funding Opportunity RFA-NS-22-017 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to have an open competition to support a Coordinating Center for the next phase of the NINDS small vessel vascular contributions to cognitive impairment and dementia (VCID) biomarkers consortium. The original consortium was established under RFA-NS-16-019 and RFA-NS-16-020. The goal of the next phase, under this FOA (Coordinating Center) and RFA-NS-20-005 (sites), is to complete clinical validation of biomarkers initially developed during the first 5-year funding cycle of this program. The Coordinating Center will consist of: (i) an Administrative Core responsible for organizing, coordinating and administratively driving Consortium activities; and (ii) a Data Core that will coordinate, receive, collect, and share data, including de-identified clinical data. The Coordinating Center will provide infrastructure and expertise to drive the consortium administratively and contribute scientifically to validation of biomarkers with specified context of use for future clinical trials, including in large phase III trials, with general and diverse populations, and for generating scientific breakthroughs in our understanding and treatment of VCID.